Dr. Elizabeth O'Day, Olaris CEO, and Dr. Mike Pellini, Managing Director of Section 32 speak on BC panel

Dr. Elizabeth O'Day and Dr. Mike Pellini discuss how far biotechnology has come in the last decade and share their insights on how robust diagnostics will usher in the future of precision medicine. Watch their panel in the recap below.

January 20, 2021

Dr. Elizabeth O'Day, Olaris CEO, and Dr. Mike Pellini, Managing Director of Section  32 speak on BC panel